Sehydrin, 60 mg 50 pcs.

Pharmacodynamics

The drug inhibits tumor growth, affects a number of biochemical parameters: inhibits monoamine oxidase activity, reduces cell membrane permeability and biomembranes of subcellular structures, is an inhibitor of xenobiotic metabolism. It has symptomatic therapeutic effect in malignant neoplasms in advanced stages. It does not have myelodepressive and other side effects which are typical for many other antitumor drugs.

Pharmacokinetics

The drug content in the blood of patients reaches a maximum 2 hours after taking 60 mg (1 tablet); 24 hours later small amounts are still detected in the serum. Blood sampling 9 hours after the end of the 30-day treatment course detects 0 to 89 ng/ml of Sehydrin® in different patients.

The pharmacokinetics of Sehydrin® has also been studied in unbred intact rats and animals with sarcoma 45. The drug is rapidly absorbed from the gastrointestinal tract; blood clearance is complete by 25-28 hours after intragastric administration at a dose of 100 mg/kg.

The maximum concentration in the blood of intact animals occurs approximately 50 minutes after administration; in tumor-bearing animals (sarcoma 45), 3 hours later.

A 3-5 times higher accumulation of the substance in the liver, kidneys and lungs compared to the blood, but not in the tumor; clearance of intact organs of healthy animals and tumor carriers ends by the end of 4 days. Urinary excretion in healthy animals lasts up to 3 days and is approximately 50% of the administered amount; in tumor carriers excretion ends between the first and second day, with only 25% of the drug excreted. The volume of distribution, in intact rats, is 14 ml, in the presence of a tumor it is 29.4 ml. Tumor carriers are prone to cumulation of Sehydrin. Sehydrin® is oxidized in the body and its undegraded part is excreted with urine, partially in acetylated form (in rats and rabbits).

Indications

• Symptomatic treatment of locally advanced and disseminated forms of malignant neoplasms.

In this case Sehydrin® has a pronounced symptomatic effect: reduction or elimination of pain syndrome (up to withdrawal), weakness, respiratory failure phenomena (dyspnea), cough, fever, improved appetite, increased motor activity. The drug is prescribed to patients with malignant tumors in advanced stages (including in the preterminal phase of the process).

Active ingredient

Hydrazine sulfate

Composition

1 tablet contains:

Active substances:

Hydrazine sulfate 60 mg.

Associates:

calcium phosphate displaced,

polyvinylpyrrolidone,

magnesium stearate,

silicon dioxide highly dispersed,

/p>

dimethicone,

talc,

polymethacrylate,

polyethylene glycol 600,

Red iron oxide (E172),

Titanium dioxide.

There are 10 tablets in the blister. The pack contains 5 blisters.

.